The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy - Trial NCT06388720
Access comprehensive clinical trial information for NCT06388720 through Pure Global AI's free database. This Phase 2 trial is sponsored by National Cancer Center, Korea and is currently Recruiting. The study focuses on Bladder Cancer. Target enrollment is 82 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
National Cancer Center, Korea
Timeline & Enrollment
Phase 2
Apr 30, 2024
Dec 31, 2027
Primary Outcome
Recurrent free survival in sequential treatment group.
Summary
The aim of this study is to evaluate the effectiveness and safety of mitomycin-c and
 gemcitabine sequential instillation in BCG unresponsive high risk non-muscle invasive bladder
 cancer patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06388720
Non-Device Trial